Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 3/20 | 0.71 |
| ▸ | KDR | P35968 | 3/20 | 0.71 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.71 |
| ▸ | PTK2 | Q05397 | 12/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.57 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.57 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.57 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.57 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.54 |
| ▸ | IGF1R | P08069 | 2/20 | 0.54 |
| ▸ | CDC7 | O00311 | 1/20 | 0.54 |
| ▸ | PLK4 | O00444 | 1/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.54 |
| ▸ | CHUK | O15111 | 1/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.54 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.54 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14214730 | 0.88 | KDR (0.82) | LCKKDRMAPK14PTK2FGFR1 | |
| SCHEMBL6478730 | 0.86 | KDR (0.77) | LCKKDRMAPK14PTK2IGF1R | |
| SCHEMBL14214727 | 0.84 | KDR (0.71) | LCKKDRMAPK14PTK2FGFR1 | |
| SCHEMBL14214680 | 0.84 | LCK (0.76) | LCKKDRMAPK14PTK2FGFR1 | |
| SCHEMBL14214615 | 0.82 | KDR (0.85) | LCKKDRMAPK14PTK2FGFR1 | |
| SCHEMBL6480028 | 0.81 | KDR (0.77) | LCKKDRMAPK14PTK2IGF1R | |
| SCHEMBL6478410 | 0.81 | KDR (0.80) | LCKKDRMAPK14PTK2IGF1R | |
| SCHEMBL14214609 | 0.81 | KDR (0.87) | LCKKDRMAPK14PTK2FGFR1 | |
| SCHEMBL14214616 | 0.80 | KDR (0.84) | LCKKDRMAPK14PTK2FGFR1 | |
| SCHEMBL14214612 | 0.79 | KDR (0.82) | LCKKDRMAPK14PTK2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6864255-B2 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | FLT4, FLT1, VEGFA | LCK 1859/4885KDR 4/4885MAPK14 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.